Armistice Capital, LLC Enanta Pharmaceuticals Inc Transaction History

Armistice Capital, LLC

  • $7.34 Billion
  • Q1 2024

A detailed history of Armistice Capital, LLC transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Armistice Capital, LLC holds 1,236,000 shares of ENTA stock, worth $15.1 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
1,236,000
Previous 2,064,000 40.12%
Holding current value
$15.1 Million
Previous $19.4 Million 11.11%
% of portfolio
0.29%
Previous 0.27%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
SELL
$10.08 - $17.46 $8.35 Million - $14.5 Million
-828,000 Reduced 40.12%
1,236,000 $21.6 Million
Q4 2023

Feb 13, 2024
SELL
$8.18 - $10.78 $294,480 - $388,080
-36,000 Reduced 1.71%
2,064,000 $19.4 Million
Q3 2023

Nov 14, 2023
BUY
$11.09 - $22.13 $709,760 - $1.42 Million
64,000 Added 3.14%
2,100,000 $23.5 Million
Q2 2023

Aug 14, 2023
BUY
$20.68 - $39.85 $496,320 - $956,400
24,000 Added 1.19%
2,036,000 $43.6 Million
Q1 2023

May 15, 2023
SELL
$38.82 - $54.59 $2.56 Million - $3.6 Million
-66,000 Reduced 3.18%
2,012,000 $81.4 Million
Q4 2022

Feb 14, 2023
BUY
$40.77 - $53.73 $244,620 - $322,380
6,000 Added 0.29%
2,078,000 $96.7 Million
Q3 2022

Nov 14, 2022
BUY
$48.29 - $71.27 $96,580 - $142,540
2,000 Added 0.1%
2,072,000 $107 Million
Q2 2022

Aug 15, 2022
BUY
$38.13 - $76.93 $36.1 Million - $72.8 Million
946,000 Added 84.16%
2,070,000 $97.8 Million
Q1 2022

May 16, 2022
BUY
$56.06 - $74.11 $3.81 Million - $5.04 Million
68,000 Added 6.44%
1,124,000 $80 Million
Q4 2021

Feb 14, 2022
SELL
$60.19 - $97.37 $46.9 Million - $75.9 Million
-780,000 Reduced 42.48%
1,056,000 $79 Million
Q3 2021

Nov 15, 2021
SELL
$41.02 - $58.65 $6.73 Million - $9.62 Million
-164,000 Reduced 8.2%
1,836,000 $104 Million
Q2 2021

Aug 16, 2021
BUY
$43.76 - $53.11 $15.4 Million - $18.7 Million
352,000 Added 21.36%
2,000,000 $88 Million
Q1 2021

May 17, 2021
BUY
$41.69 - $54.95 $12.2 Million - $16 Million
292,000 Added 21.53%
1,648,000 $81.3 Million
Q4 2020

Feb 16, 2021
BUY
$41.16 - $47.47 $34.2 Million - $39.5 Million
832,000 Added 158.78%
1,356,000 $57.1 Million
Q3 2020

Nov 16, 2020
BUY
$43.36 - $53.53 $8.67 Million - $10.7 Million
200,000 Added 61.73%
524,000 $24 Million
Q2 2020

Aug 14, 2020
SELL
$46.37 - $57.58 $11.3 Million - $14 Million
-244,000 Reduced 42.96%
324,000 $16.3 Million
Q1 2020

May 15, 2020
BUY
$40.22 - $62.0 $7 Million - $10.8 Million
174,105 Added 44.2%
568,000 $29.2 Million
Q4 2019

Feb 14, 2020
SELL
$57.95 - $66.61 $10.8 Million - $12.4 Million
-186,105 Reduced 32.09%
393,895 $24.3 Million
Q3 2019

Nov 14, 2019
BUY
$60.08 - $88.17 $12 Million - $17.6 Million
200,000 Added 52.63%
580,000 $34.8 Million
Q2 2019

Aug 14, 2019
BUY
$81.3 - $97.35 $650,400 - $778,800
8,000 Added 2.15%
380,000 $32.1 Million
Q1 2019

May 15, 2019
SELL
$69.08 - $105.66 $8.84 Million - $13.5 Million
-128,000 Reduced 25.6%
372,000 $35.5 Million
Q4 2018

Feb 14, 2019
BUY
$65.41 - $84.65 $2.88 Million - $3.72 Million
44,000 Added 9.65%
500,000 $35.4 Million
Q3 2018

Nov 14, 2018
BUY
$85.46 - $126.37 $28.4 Million - $42 Million
332,000 Added 267.74%
456,000 $39 Million
Q2 2018

Aug 14, 2018
SELL
$81.85 - $120.51 $654,800 - $964,080
-8,000 Reduced 6.06%
124,000 $14.4 Million
Q1 2018

May 15, 2018
BUY
$57.91 - $92.15 $2.55 Million - $4.05 Million
44,000 Added 50.0%
132,000 $10.7 Million
Q4 2017

Feb 14, 2018
SELL
$45.65 - $59.37 $913,000 - $1.19 Million
-20,000 Reduced 18.52%
88,000 $5.16 Million
Q3 2017

Nov 14, 2017
BUY
$37.91 - $46.8 $4.09 Million - $5.05 Million
108,000
108,000 $5.05 Million

Others Institutions Holding ENTA

# of Institutions
108
Shares Held
21.7M
Call Options Held
9.4K
Put Options Held
3.3K
View Full List

About ENANTA PHARMACEUTICALS INC

ENTA Quotes by TradingView
  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $254M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email